Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00071526 · ClinicalTrials.gov registry record

Urinary Vitamin C Loss in Diabetic Subjects

A clinical trial of Diabetes, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).

Recruiting
Registry status
5,000
Enrollment target
1
Study location

NCT00071526: Recruiting study of Diabetes, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).

NCT00071526 is a study of Diabetes that is actively recruiting participants, run by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The registered enrollment target is 5,000 participants, above the 3,013-participant average among 338 other Diabetes trials with a reported enrollment target (66% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00071526, a study of Diabetes, is actively recruiting participants, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).

RECRUITING
Registry status
5,000 participants
Enrollment target
1
Study location

Study Summary

Several studies have reported that diabetic subjects have lower plasma vitamin C concentrations than non-diabetic subjects. Although urinary vitamin C loss in diabetic subjects was reported to be increased in two studies, these are difficult to interpret due to lack of controlled vitamin C intake, inadequate sampling, lack of control subjects, or methodology uncertainties in vitamin C assay and sample processing. Consequently, it is unclear whether diabetic subjects truly have both low plasma and high urine vitamin C concentrations. We propose that low plasma vitamin C concentrations in diabetic subjects are due in part to inappropriate renal loss of vitamin C in these subjects but not in healthy controls. We will study nondiabetic controls and cohorts with diabetes. Vitamin C concentrations in plasma, RBCs, and urine will be measured in outpatients. In those willing to be admitted to the Clinical Center, we will measure vitamin C pharmacokinetics to determine the relative bioavailability for vitamin C in individuals with and without abnormal urinary loss of vitamin C (or renal leak). Single nucleotide polymorphisms (SNPs) will be determined in genomic DNA responsible for the two proteins mediating sodium dependent vitamin C transport, SVCT1 and SVCT2. We will also explore mechanisms underlying abnormal urinary vitamin C loss....

Primary Outcome

Measurements of plasma, neutrophil and red blood cell vitamin c concentrations in diabetic subjects as compared to healthy controls.

Conditions Studied

Study Locations (1)

Maryland

  • National Institutes of Health Clinical Center - Bethesda

Trial Details

FieldValue
Enrollment Target 5,000 participants
Start Date 2006-04-11

What NCT00071526 shows while recruiting

NCT00071526 is an observational study that tracks outcomes without assigning an intervention. Its 5,000 participants enrollment target places it among the larger protocols in the corpus, above the 3,013-participant average among 338 other Diabetes trials with a reported enrollment target (66% higher).

The record links to 1 condition, with Diabetes appearing as the primary indexed condition, and to 0 interventions.

NCT00071526 reports a single indexed study location in Maryland.

Frequently Asked Questions

What is clinical trial NCT00071526 about?

NCT00071526 is a clinical study titled "Urinary Vitamin C Loss in Diabetic Subjects". Several studies have reported that diabetic subjects have lower plasma vitamin C concentrations than non-diabetic subjects. Although urinary vitamin C loss in diabetic subjects was reported to be increased in two studies, these are difficult to interpret due to lack of controlled vitamin C intake, i...

What is the current status of trial NCT00071526?

This trial is currently recruiting. The enrollment target is 5,000 participants. The study started on 2006-04-11.

What conditions does trial NCT00071526 study?

This clinical trial studies the following conditions: Diabetes.

Who is sponsoring clinical trial NCT00071526?

This trial is sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), which has 490 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00071526 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Diabetes

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00071526's enrollment target sits among peer trials

5,000 14th of 338 higher than 323 of 338 other Diabetes trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Diabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00060541 · 5,000 participants

    Evaluation and Treatment of Neurosurgical Disorders

  • NCT00575081 · 5,000 participants

    Physiological Brain Atlas Development

  • NCT00736749 · 5,000 participants

    Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies

  • NCT00900198 · 5,000 participants

    Collection of Tissue Samples for Cancer Research

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT00071526, the US trial registry maintained by the National Library of Medicine. NCT00071526 (large enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.